Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: Ketogenic Diet, Standard Diet; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pancreatic Cancer Non-resectable
Interventions: Folfirinox, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Achondroplasia
Interventions: Not listed
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 0 Years to 8 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Little Rock, Arkansas • Oakland, California • Aurora, Colorado + 7 more

Conditions: Chronic Diabetic Foot Ulcers
Interventions: Extracorporeal Shockwaves; Device
Lead sponsor: Tissue Regeneration Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • The Bronx, New York • Akron, Ohio + 2 more

Conditions: Papillary Carcinoma of Thyroid Gland, Metastatic Medullary Thyroid Cancer, Follicular Thyroid Cancer Lymph Node Metastasis
Interventions: Ferumoxytol, Nanoparticle MRI; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Obesity, Morbid, Obesity; Endocrine, Bariatric Surgery Candidate
Interventions: Gastric mucosal devitalization; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 28 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Adapted Family History Screening Program; Other
Lead sponsor: Emory University; Other
Eligibility: 25 Years and older · Female only
Enrollment: 3,209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
Interventions: GW786034; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 5
States / cities: Atlanta, Georgia • Austin, Texas • Bedford, Texas + 2 more

Conditions: Pancreatic Cyst, Pancreatic Pseudocyst, Pancreatic Neoplasm
Interventions: DNA analysis of pancreatic cyst fluid / buccal swab; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 7
States / cities: Indianapolis, Indiana • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: Growth Hormone Deficiency
Interventions: growth hormone (Nutropin); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Month to 17 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: ravuconazole; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 11
States / cities: Clovis, California • Los Angeles, California • Newport Beach, California + 6 more

Conditions: Diabetes Mellitus, Type 2, Peripheral Arterial Disease
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 88
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more

Conditions: Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions: CGM; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbia, Maryland

Conditions: Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
Interventions: Ibrutinib, Durvalumab; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 13 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Aliskiren, Irbesartan, Captopril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatic Cancer
Interventions: cisplatin, gemcitabine hydrochloride, surgical procedure, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: New York, New York

Conditions: Biliary Tract Diseases, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Barrett Esophagus
Interventions: ExSpiron Respiratory Variation Monitor; Device
Lead sponsor: Donald Mathews; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Cardiovascular Disease, Hypertension, Diabetes, Obesity
Interventions: Lay Health Promoter (LHP) with maintenance; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 392 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions: AZD 1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more

Conditions: Low-GI Dietary Education, ADA Dietary Education
Interventions: Low GI, ADA diet; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Diabetes, Inflammation
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Achondroplasia
Interventions: TransCon CNP; Drug
Lead sponsor: Ascendis Pharma Growth Disorders A/S; Industry
Eligibility: 3 Years to 15 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2039
U.S. locations: 8
States / cities: Little Rock, Arkansas • Aurora, Colorado • Wilmington, Delaware + 5 more

Conditions: Advanced Solid Tumor
Interventions: SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more

Search by objective public record fields.

Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes

Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia

Safety & Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Diabetic Foot Ulcers

Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study

Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Cancer Detection in Pancreatic Cysts

304-C03/L3301n: Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer

An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy

The GoodNEWS Lifestyle Enhancement Program

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Diabetic Educational Eating Plan

Vascular Risk Progression in Normal and Diabetic Control Subjects.

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

Study of SRF617 in Patients With Advanced Solid Tumors